Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Kinarus Therapeutic Holding AG

Kinarus Therapeutics Announces Personnel Change
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Shareholders Approve All Board Proposals at the 2023 Annual General Meeting
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics signed subordinated bridge loans to ensure further liquidity
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Publishes Invitation to the 2023 Annual General Meeting
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Group Reports 2022 Annual Results
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics signed CHF1.5 million convertible loan agreement with ChaoDian (Hangzhou) Investment Management
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Reports Key Unaudited Full Year 2022 Figures
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Holding AG ("Kinarus") receives deadline extension from SER for publication of its 2022 annual financial report
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical Trial Progress Update
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Provides Strategic Update
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety
From Kinarus Therapeutic Holding AG
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.